{"id":"pegylated-recombinant-factor-viii","safety":{"commonSideEffects":[{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Nausea"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This modification allows for less frequent dosing and improved stability of the protein. PEGylation also reduces the immunogenicity of the protein, which can lead to fewer side effects and improved efficacy.","oneSentence":"PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:02.003Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia A, for the prevention and control of bleeding episodes"},{"name":"Surgery in patients with hemophilia A"}]},"trialDetails":[{"nctId":"NCT04158934","phase":"","title":"A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baxalta now part of Shire","startDate":"2020-07-09","conditions":"Hemophilia A","enrollment":207},{"nctId":"NCT02615691","phase":"PHASE3","title":"A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-12","conditions":"Hemophilia A","enrollment":120},{"nctId":"NCT05707351","phase":"PHASE3","title":"A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-03-27","conditions":"Hemophilia A","enrollment":37},{"nctId":"NCT04690322","phase":"PHASE4","title":"POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2021-04-15","conditions":"Hemophilia A, Factor VIII","enrollment":28},{"nctId":"NCT03169972","phase":"","title":"ADYNOVATE Drug Use-Results Survey","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-02-01","conditions":"Hemophilia A","enrollment":135},{"nctId":"NCT04941898","phase":"","title":"A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-06-30","conditions":"Hemophilia A","enrollment":16},{"nctId":"NCT02078427","phase":"","title":"ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-06-28","conditions":"Hemophilia A","enrollment":951},{"nctId":"NCT06142552","phase":"PHASE3","title":"Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein","status":"RECRUITING","sponsor":"Jiangsu Gensciences lnc.","startDate":"2023-12-27","conditions":"Severe Hemophilia A","enrollment":120},{"nctId":"NCT03824522","phase":"","title":"Post Marketing Surveillance Study for ADYNOVATE in South Korea","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-02-25","conditions":"Hemophilia A","enrollment":341},{"nctId":"NCT04876365","phase":"","title":"A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-30","conditions":"Hemophilia A","enrollment":153},{"nctId":"NCT02585960","phase":"PHASE3","title":"BAX 855 PK-guided Dosing","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-11-23","conditions":"Hemophilia A","enrollment":135},{"nctId":"NCT01913405","phase":"PHASE3","title":"Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-12-20","conditions":"Hemophilia A","enrollment":30},{"nctId":"NCT02210091","phase":"PHASE3","title":"BAX 855 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2014-10-31","conditions":"Hemophilia A","enrollment":75},{"nctId":"NCT01945593","phase":"PHASE3","title":"BAX 855 Continuation","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-10-15","conditions":"Hemophilia A","enrollment":218},{"nctId":"NCT01736475","phase":"PHASE2, PHASE3","title":"Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-01-31","conditions":"Hemophilia A","enrollment":159},{"nctId":"NCT01599819","phase":"PHASE1","title":"BAX 855 Dose-Escalation Safety Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-09-30","conditions":"Hemophilia A","enrollment":19},{"nctId":"NCT00623727","phase":"PHASE2","title":"BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A","status":"TERMINATED","sponsor":"Bayer","startDate":"2008-06","conditions":"Hemophilia A","enrollment":143},{"nctId":"NCT00245297","phase":"PHASE2","title":"Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.","status":"COMPLETED","sponsor":"Recoly N.V.","startDate":"2005-10","conditions":"Haemophilia A","enrollment":16}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"H1N1 INFLUENZA"},{"count":1,"reaction":"PULMONARY TUBERCULOSIS"},{"count":1,"reaction":"TUBERCULOSIS"}],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAX 855","TAK-660","BAX855","ADYNOVATE"],"phase":"phase_3","status":"active","brandName":"PEGylated Recombinant Factor VIII","genericName":"PEGylated Recombinant Factor VIII","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"PEGylated Recombinant Factor VIII is a recombinant form of human factor VIII that is modified with polyethylene glycol (PEG) to prolong its half-life. Used for Hemophilia A, for the prevention and control of bleeding episodes, Surgery in patients with hemophilia A.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":6},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}